Immunogenicity of BNT162b2 vaccine booster against SARS-CoV-2 Delta and Omicron variants in nursing home residents: A prospective observational study in older adults aged from 68 to 98 years

Summary: Background: The present study aimed to evaluate the persistent immunogenicity offered by a third dose of BNT162b2 against Delta and Omicron variants, in nursing home (NH) residents. Methods: In this monocenter prospective observational study, anti-spike IgG levels, S1 domain reactive T cel...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Enagnon Kazali Alidjinou, Julie Demaret, Bénédicte Corroyer-Simovic, Julien Labreuche, Anne Goffard, Jacques Trauet, Daniela Lupau, Sophie Miczek, Fanny Vuotto, Arnaud Dendooven, Dominique Huvent-Grelle, Juliette Podvin, Daniel Dreuil, Karine Faure, Dominique Deplanque, Laurence Bocket, Alain Duhamel, Annie Sobaszek, Didier Hober, Michael Hisbergues, Francois Puisieux, Brigitte Autran, Yazdan Yazdanpanah, Myriam Labalette, Guillaume Lefèvre
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Elsevier 2022-06-01
Saila:	The Lancet Regional Health. Europe
Gaiak:	BNT162b2 vaccine Boost SARS-CoV-2 Delta Omicron Older people
Sarrera elektronikoa:	http://www.sciencedirect.com/science/article/pii/S2666776222000783
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!